THE DNDN parallels are obvious - the trial has a compelling HR value (= 0.753), and if the drug can hold its own in the most difficult of all cancers, then the stock ........well at 63c, I dont have to tell you.
There will be a PR in the morning but these posts (and previous posts here) can help you plan ahead.
Also check out the PLOTS in the GNVC iBox (there is even a Survey there to pick your favorite).